US equities |
TSLA $391.16 ▲+5.09% MU $901.98 ▲+2.78% NVDA $216.10 ▲+2.44% SPCX $146.96 ▼-0.36% META $628.18 ▼-2.25% AAPL $343.86 ▼-1.11% SNDK $1,255.01 ▲+1.37% INTC $90.53 ▲+4.10%
FinancialContent

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

0.6500 UNCHANGED
Delayed Quote Updated: 3:55 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Aldeyra Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Unusual volume stocks are being observed in Monday's session. ↗
These stocks have an unusual volume in today's session 
Via Chartmill
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX
From Pomerantz LLP
Via GlobeNewswire
News headline image
What's going on in today's session ↗
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
11 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
ALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA Law
From Bleichmar Fonti & Auld LLP
Via Business Wire
News headline image
The market is filled with gapping stocks in Thursday's session. ↗
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
Crude Oil Dips 7%; ISM Services PMI Falls In March ↗
 
Via Benzinga
News headline image
Aldeyra Stock Slumps After FDA Says Investigational Drug For Dry Eyes Treatment Failed To Demonstrate Efficacy – Retail Stays Optimistic ↗
Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with... 
Via Stocktwits
Topics Artificial Intelligence Bankruptcy
News headline image
These stocks that are showing activity before the opening bell on Thursday. ↗
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Dow Tumbles Over 1,100 Points; US Initial Jobless Claims Fall ↗
 
Via Benzinga
Topics Stocks
News headline image
FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns ↗
The FDA rejected Aldeyra's resubmission for reproxalap, citing efficacy concerns. The company plans another trial and aims to resubmit the NDA by mid-2025. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30% ↗
Aldeyra Therapeutics announces successful results from its Phase 3 clinical trial of reproxalap. The results support a potential 2024 NDA resubmission. 
Via Benzinga
News headline image
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
From Aldeyra Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >